8635 W. 3rd St. Suite #485-W
Los Angeles, CA 90048
(310) 652-9162

Shrinath Barathan, M.D.

Dr. Shrinath Barathan

View Complete CV

Professional Experience

Clinical Chief of Nephrology 2013–Present Cedars Sinai Medical Center, Los Angeles.
Assistant Professor of Medicine 2011–Present. David Geffen School of Medicine, UCLA.
Clinical Instructor 2004-2011. David Geffen School of Medicine, UCLA.
Attending Staff Physician 2003–Present. Cedars Sinai Medical Center, Los Angeles.
Preceptor 2012–Present.

School of Nursing. California State University, Los Angeles.

Partner. 2003–Present.

Tower Nephrology Medical Group, Los Angeles.

Assistant Medical Director.

2009–Present. Crescent Heights Dialysis Center. Los Angeles.


Committees At Cedars Sinai Medical Center

2013–Present Department of Medicine Performance Improvement Committee
2008 - Present Pharmacy and Therapeutics Commitee
2010 - Present Joint Dialysis Oversight Committee
2010 - Present Best Practices for Continuous Renal Replacement Therapy Committee
2010 - Present

Cardiac Surgical ICU Innovation Project

2010 - Present

Vaptan Task Force

2011-Present

Code Sepsis Committee - Clinical Team to device protocols for septic patients

2011-Present

Electronic Medical Record. CS Link Nephrology Task Force


Education And Training

College

BS in Chemistry. Presidency College, Madras University, India. 1983-1986.

Medical

MD. 1987-1993. National Pirogov Memorial Medical University, Vinnytsya.
Ukraine.

Residency

Internal Medicine, 1997-2000. MetroHealth Medical Center, The Rammelkamp Center for Education and Research, MetroHealth Medical Center. Case Western Reverse University, Cleveland, Ohio.

Fellowship

Nephrology, 2000-2003. University Hospitals, MetroHealth Medical Center, VA Medical Center, Cleveland, Ohio. Case Western Reserve University.


Awards And Certifications

1987

Fully funded scholarship to medical school sponsored by Governments of India and USSR.

1993

Certified Teacher of Russian Language.

2000

Diplomate in Internal Medicine, American Board of Internal Medicine.

2000

ACLS Provider

2000

BLS Provider

2003

Board Certified, Subspecialty Board in Nephrology, American Board of Internal Medicine.


Licensures

Medical

California State Medical Board


Other Services

President. 1986-1987. Foreign Students Association. National Pirogov Memorial Medical University, Vinnytsya. Ukraine.

Languages Spoken

English, Russian, Malayalam and Tamil

 


Scientific Presentations

  • Senior Resident Grand Rounds, 2000, "Progression of Chronic Renal Disease", Metro Health Medical Center, Cleveland, OH
  • Research Days 2000, "Comparison of mRNA kidney expression profiles generated by Serial Analysis of Gene Expression (SAGE) to identify candidate nephropathy genes in C57BL/6-Os/ + Versus ROP-Os/ + mice", Rammelkamp Center for Education and Research, MetroHealth Medical Center, Cleveland OH.
  • Research Days 2002, "The cell guidance molecule neuropilin-2 is under expressed in podocytes of sclerosis-prone ROP-Os/+, but not C57Bl/6-Os/+mice", Rammelkamp Center for Education and Research, MetroHealth Medical Center, Cleveland, OH.
  • Journal Club, 2002, "Treatment of Lupus Nephritis", University Hospital of Cleveland, Cleveland, OH.
  • Journal Club, 2003. "Major Outcomes in High-Risk Hypertensive Patients Randomized Patients Randomized to ACE Inhibitor or Calcium Channel Blocker vs. Diuretic" The ALLHAT Trial. University Hospitals of Cleveland, Cleveland, OH.

Clinical Study Location

  • Tower Nephrology Medical Group, 8635 W. 3RD ST #485W Los Angeles, CA 90048

    Da Vita of Beverly Hills, 50 N. La Cienega blvd. #300 Beverly hills, CA 90211

    Da Vita of Crescent Heights, 8151 Beverly blvd Los Angeles, CA 90048


Clinical Studies

2013 ICH Good Clinical Practice for Clinical Trial Sites (Certificates)

Sub-Investigator 2014 Ferumoxytol for Anemia of CDK Trial (FACT): A Phase IV, open Label, Multicenter Trial, with MRI Substudy, of Repeated Doses Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Definiency Anemia (IDA) in Chronic Kidney Disease (CDK) Patients on Hemodialysis
Sub-Investigator 2014 A Multicenter Single-arm Extention Study to Describe the Long- term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Sub-Investigator 2013 A randomized, Double-blind, Placebo-controlled, Phase 3 Study to assess the Efficacy and Safety of AMG 416 in the Treatment of Seconday Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis.
Sub-Investigator 2013 ZS-003: “A Phase III multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia.
Sub-Investigator 2013 Randomized, Double-blind, Parallel-group, Multicenter study to evaluate the efficacy and safety of HX575 Epoetin alfa cs. US licensed Epoetin alfa (Epogen/Procrit) in the treatment of anemia associated with chronic kidney disease.
Sub-Investigator 2013 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults With Type 2 Diabetes and Overt Nephropathy Study #B1261007-1137
Sub-Investigator 2012 A phase 2b, Prospective, Double- Blind, Placebo- Controlled, Multicenter to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedence, in Type 2 Diabetic Subjects with Nephropathy
Sub-Investigator 2011 A Three-Period, 58-Week Safety and Effiancy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis
Sub-Investigator 2011 Bardoxolone Methyl Evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (Beacon)
Sub-Investigator 2011 A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study

2010 GCP Certified by the National Cancer Institute

Sub-Investigator 2010

A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease.

Sub-Investigator 2010

Study to evaluate the improved management of iPTH with paracalcitol- centered therapy vs. cinacalcet therapy with low-dose vitamin d in hemodialysis patients with secondary hyperparathyroidism.

Sub-Investigator 2009

A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor.

Sub-Investigator 2008

Phase 2, randomized, double-blind, placebo-controlle, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia.

Sub-Investigator 2007

A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin

Sub-Investigator 2007

Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic haemodialysis

Sub-Investigator 2007

A Phase IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects treated with lanthanum Carbonate (Fosrenol ®)

Sub-Investigator 2007

A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center Injections.

Sub-Investigator 2007

Prospective, Open Label, Randomized multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis.

Sub-Investigator 2007

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease.

Sub-Investigator 2007

A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once- Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease

Sub-Investigator 2007

An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency

Sub-Investigator 2006

A randomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2diabetes mellitus and diabetic nephropathy.

Sub-Investigator 2006

Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular Events.

Sub-Investigator 2006

A Phase III Study if the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis.

Sub-Investigator 2005

An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease.

Sub-Investigator 2004

Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis.

Sub-Investigator 2004

Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis.


Original Contributions

  • Identification of nephropathy candidate genes by comparing sclerosis-prone and sclerosis-resistant mouse strain kidney transcriptomes. El-Meanawy A, Schelling JR, Iyengar SK, Hayden P, Barathan S, Goddard K, Pozuelo F, Elashi E, Nair V, Kretzler M, Sedor JR. BMC Nephrol. 2012 Jul 19;13:61. doi: 10.1186/1471-2369-13-61.

    Serial analysis of gene expression. El-Meanawy MA, Barathan S, Hayden PS, Iyengar SK, Schelling JR, Sedor JR. Methods Mol Med. 2003;86:257-74.

    Generation of kidney transcriptomes using serial analysis of gene expression. Schelling JR, El-Meanawy MA, Barathan S, Dodig T, Iyengar SK, Sedor JR. Exp Nephrol. 2002;10(2):82-92.


Reviews

  • M.A. El-Meanawy, J.R. Schelling, S. Barathan, S.K. Iyengar and J.R. Sedor. Serial analysis of gene expression (SAGE). In: Methods in Molecular Medicine: Renal Disease. Guide to Technical Approaches.
    M.S. Goligorsky, ed. The Humana Press, Totowa, NJ, in press 2002.

Abstracts

  • Goddard KA, El-Meanawy A, Schelling JR, Elashi E, Barathan S., Konieczkowski M., Kamat S, Koepke S, Covie A, Sedor JR and Iyengar SK. Comparison of mRNA kidney expression profiles generated by serial analysis of gene expression (SAGE) to identify candidate nephropathy genes in C57BL/6Os/+ versus ROP-Os/+mice. Am J Hum Genet 67:1456T, 2000. El-Meanawy, A., J. Schelling, E. Elashi, S. Barathan, M. Konieczkowski, S. Kamaet, A. Koepke,
  • K. Goddard, A. Covic, S Iyengar and J. Sedor. Comparison of mRNA kidney expression profiles generated by serial analysis of gene expression to identify candidate nephropathy genes in C57BL/6-Os/+ versus ROP-Os/+mice. J. Am Soc. Nephrol, 11:617A, 2000.
  • J.R. Schelling, A. El-Meanawy, E. Elashi, S. Barathan, M. Konieczkowski, S. Kamat, A. koepke, K. Goddard, A. Covic, S.I. Iyanar and J.R. sedor. Comparison of mRNA kidney expression profiles generated by serial analysis of gene expression (SAGE) to identify candidate nephropathy genes in C57BL/6-Os/+ versus ROP-Os/+mice. Nephrology, Dialysis and Transplantation 15:A34, 2000.
  • El-Meanawy, S. Barathen, M. Konieczkoski, E. Elashi A. Covic, T. Dodig, S. Khan, A. Koepke, F. Pozuelo, K. Goddard, S. Iyangar, J.R. Schelling and J.R. Sedor. Gene expression profiles generated by serial analysis of gene expression (SAGE) identify candidate molecular pathways regulating progressive glomerulosclerosis. Nephrology, Dialysis and Transplantation 16:A38,2001.
  • El-Meanawy, M.A., S. Barathan, T. Dodig, E. Elashi, K. Goddard, S. K. Iyengar, J.R. Schelling and John R. Sedor. Kidney transcriptome profiles generated by serial analysis of gene expression identify candidate molecular pathways regulating progressive glomerulosclerosis. J. Am. Soc. Nephrol. 12:617A, 2001.
  • Barathan, S., M. Konieczkowski, A. El-Meanawy*, S. Khan, B. Wang, T. Dodig, S.K. Iyengar, J.R. Schelling and J.R. Sedor. Expression analysis demonstrated the cell guidance signal neuropilin 2b (nrp2) is reduced in sclerosis-prone Rop-Os/+ but not sclerosis-resistant C57-Os/+ mouse kidneys. J. Am. Soc. Nephrol. 12:617A, 2001.
  • P. Hayden, M.A. El-Meanawy, S. Barathan, G. Jarad, M. Srichai, M. Konieczkowski, S. Iyengar, J.R. Schelling, J.R. Sedor. Serial Analysis of Gene expression (SAGE)- Generated Libraried from Kidneys of Sclerosis-Prone and Sclerosis-Resistant Mice Identify aRenal Disease-Associated Replicon. J. Am Soc. Nephrol. 13:118A, 2002.
  • S. Barathan, S. Iyengar, L. Bruggeman, P. Mundel, M. El-Meanawy, M. Konieczkowski, J. Schelling, J. Sedor. The Cell Guidance Molecule Neuropilin-2 Is Underexpressed in Podocytes of Sclerosis-Prone ROP-Os/+, but Not C57B1/6-Os/+Mice. J. Am Soc. Nephrol.13:124A, 2002.
  • M.B. Srichai, M. Konieczkowski, S. Barathan, S. Khan, P. Mundel, S. Lee, L. Bruggeman, J.R. Schelling, J.R. Sedor. A Novel WT1 Co-Regulator That Shuttles between Nucleus and Plasma Membrane, J. Am. Soc. Nephrol. 13:16A, 2001